• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    12/28/22 8:06:54 AM ET
    $ALZN
    $ATIP
    $ATNF
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $ALZN alert in real time by email

    Gainers

    • Minerva Surgical (NASDAQ:UTRS) shares increased by 111.6% to $0.34 during Wednesday's pre-market session. The company's market cap stands at $9.9 million.
    • Jounce Therapeutics (NASDAQ:JNCE) shares rose 73.58% to $1.28. The market value of their outstanding shares is at $66.1 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 55.61% to $6.1. The market value of their outstanding shares is at $9.2 million.
    • Alzamend Neuro (NASDAQ:ALZN) stock rose 21.68% to $0.73. The market value of their outstanding shares is at $70.1 million.
    • Journey Medical (NASDAQ:DERM) stock rose 17.25% to $1.36. The market value of their outstanding shares is at $24.0 million.
    • NexImmune (NASDAQ:NEXI) stock increased by 13.53% to $0.25. The company's market cap stands at $6.5 million.

    Losers

    • NeuBase Therapeutics (NASDAQ:NBSE) shares decreased by 13.6% to $0.19 during Wednesday's pre-market session. The company's market cap stands at $6.2 million.
    • Quotient (NASDAQ:QTNT) shares decreased by 13.52% to $0.32. The company's market cap stands at $1.1 million.
    • Benitec Biopharma (NASDAQ:BNTC) shares decreased by 11.53% to $0.14. The market value of their outstanding shares is at $3.9 million.
    • Exicure (NASDAQ:XCUR) shares fell 11.3% to $1.1. The market value of their outstanding shares is at $5.4 million.
    • 180 Life Sciences (NASDAQ:ATNF) shares declined by 10.87% to $1.74. The company's market cap stands at $6.4 million.
    • ATI Physical Therapy (NYSE:ATIP) stock declined by 9.71% to $0.27. The company's market cap stands at $56.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALZN
    $ATIP
    $ATNF
    $BNTC

    CompanyDatePrice TargetRatingAnalyst
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    KALA BIO Inc.
    $KALA
    9/8/2025$30.00Outperform
    Mizuho
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    KALA BIO Inc.
    $KALA
    7/11/2025$12.00Buy
    Ladenburg Thalmann
    Benitec Biopharma Inc.
    $BNTC
    7/7/2025Buy
    TD Cowen
    More analyst ratings

    $ALZN
    $ATIP
    $ATNF
    $BNTC
    SEC Filings

    View All

    SEC Form 144 filed by KALA BIO Inc.

    144 - KALA BIO, Inc. (0001479419) (Subject)

    3/12/26 5:40:34 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Alzamend Neuro Inc.

    10-Q - Alzamend Neuro, Inc. (0001677077) (Filer)

    3/11/26 4:30:55 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Alzamend Neuro Inc.

    424B5 - Alzamend Neuro, Inc. (0001677077) (Filer)

    3/6/26 4:46:18 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATIP
    $ATNF
    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    2/19/26 2:27:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Purdy Brendan P.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:16:24 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Berger Chaim D.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:15:14 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATIP
    $ATNF
    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

    DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. Leading the narrative is KALA BIO (NASDAQ:KALA), which announced it expects to deploy its first commercial AI agent within approximately two weeks as part of the rebranded Researgency.ai platform. The company is attempting to reposi

    3/11/26 10:00:26 AM ET
    $CYN
    $DOMO
    $KALA
    EDP Services
    Technology
    Computer Software: Prepackaged Software
    Biotechnology: Pharmaceutical Preparations

    Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

    ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market. Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical industry through its Researgency.ai platform, deploying purpose-built AI agents that handle the r

    3/11/26 6:30:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

    HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highlight the key clinical results observed to date for OPMD Patients enrolled into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301 to transform the treatment l

    3/10/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATIP
    $ATNF
    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KALA BIO downgraded by Mizuho with a new price target

    Mizuho downgraded KALA BIO from Outperform to Neutral and set a new price target of $1.50

    9/30/25 9:48:28 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by H.C. Wainwright

    H.C. Wainwright downgraded KALA BIO from Buy to Neutral

    9/29/25 1:25:35 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded KALA BIO from Buy to Neutral

    9/29/25 9:48:46 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATIP
    $ATNF
    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $19,999,994 worth of shares (1,481,481 units at $13.50) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    11/10/25 9:51:33 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATIP
    $ATNF
    $BNTC
    Leadership Updates

    Live Leadership Updates

    View All

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATIP
    $ATNF
    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ALZN
    $ATIP
    $ATNF
    $BNTC
    Financials

    Live finance-specific insights

    View All

    Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar

    11/12/25 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure, Inc. Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended September 30, 2025, as compared to $0 for the quarter ended September 30, 2024. The increase in R&D expense of $0.9 million for the three months ended September 30, 2025 was due to incurring research and developmen

    11/7/25 4:00:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

    SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2025 financial results after the U.S. financial markets close on Wednesday, November 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the

    11/5/25 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care